Meriofert

Follicle-Stimulating Hormone / Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular, subcutaneous use. It treats anovulation and supports ovarian stimulation in assisted reproductive technology in women. It is indicated for induction of ovulation in women with anovulatory disorders and for controlled ovarian stimulation during in‑vitro fertilisation cycles. GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance through reliable cold‑chain logistics.

Meriofert, a gonadotropin used in reproductive medicine, is indicated for: Anovulation: Induces ovulation in women who do not ovulate spontaneously. Polycystic ovary syndrome (PCOS): Facilitates follicular growth and ovulation in PCOS patients. Assisted reproductive technology (IVF): Provides controlled ovarian stimulation to generate multiple mature follicles for egg retrieval.

Adverse reactions to Meriofert may vary in frequency and severity.

Common Side Effects: - Injection site pain - Abdominal bloating - Nausea - Mild ovarian hyperstimulation

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome - Multiple pregnancy - Ovarian torsion - Anaphylactic reaction

When using Meriofert, clinicians should observe several precautionary measures to minimise risks.

Pregnancy testing: Verify that the patient is not pregnant before initiating therapy. Ovarian monitoring: Perform serial ultrasound examinations to assess follicular response. Risk of OHSS: Use the lowest effective dose and monitor estradiol levels to detect early signs. Multiple gestation risk: Counsel patients about the increased chance of twins or higher-order pregnancies. Allergy assessment: Screen for hypersensitivity to gonadotropin preparations. Store at 2-8°C: Keep refrigerated, protect from light, and avoid freezing or shaking.

Meriofert can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - GnRH antagonists: May blunt the ovarian response to FSH/LH. - Oral estrogen‑containing contraceptives: Can suppress endogenous gonadotropin activity. - Chemotherapy agents: May impair ovarian function and reduce effectiveness. - Concurrent use of other gonadotropins: Increases risk of ovarian hyperstimulation.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: May affect ovarian responsiveness; monitor thyroid status. - Glucocorticoids: Can mask early symptoms of OHSS; observe patient closely. - Anticoagulants: Monitor injection sites for prolonged bleeding.